A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 72
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : VDZ
Long Form : vedolizumab
No. Year Title Co-occurring Abbreviation
2020 A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. CDST
2020 A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. ADA, CD, CI, OR
2020 Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease. CD, IBD, TNF
2020 Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. IBDs
2020 Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. IL, UC
2020 Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. IFX, TNF, UC
2020 Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naive Patients with Moderate-to-Severe Ulcerative Colitis in Japan. QALYs, TNF, UC
2020 Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE). Be-RELIVE, CD, UC
2020 Effectiveness and safety of vedolizumab in biologically naive patients: A real-world multi-centre study. CD, UC
10  2020 Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response. CD, CRP, HBI, SCCAI, UC
11  2020 Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. ADA, BF, GOL, IFX, NBF, NMA, SLR, TOF, UST
12  2020 Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations. DBS, TDM
13  2020 Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice. FC
14  2020 Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario. CD, IBD, UC
15  2020 Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: a case report and review of the literature. HHV, HIV, KS
16  2020 Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases. CD, IBD, UC
17  2020 Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series. CONFER, ECCO, EN, IBD, MCD, PG, UST
18  2020 Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study. CD, IBD, UC
19  2020 Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review. anti-TNFalpha, AP, biologic-naive, CD, CR, LS, RB, SF, UC
20  2020 Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. SFCR, UC
21  2020 Vedolizumab (VDZ) for UC and CD: Still Safe and Effective After All These Years. ---
22  2020 Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. UC
23  2020 Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. CD, TNF, UC
24  2020 Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy. UC
25  2020 Vedolizumab Therapy in Children With Primary Sclerosing Cholangitis: Data From the Pediatric PSC Consortium. IBD, PSC
26  2019 alpha4beta7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis. MMF, UC
27  2019 Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. ADA, IFX, UC
28  2019 Comparative safety and effectiveness of tumor necrosis factor alpha antagonists and vedolizumab in elderly IBD patients: a multicentre study. CD, IBD, OR, UC
29  2019 Comparison of the integrin alpha4beta7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis. IBD, UC
30  2019 Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. TLs
31  2019 Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience. IBD, RWE
32  2019 Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. ---
33  2019 Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study. IBD
34  2019 Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center. ---
35  2019 Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. IBD, TNF
36  2019 Persistence with Biologic Treatment in Patients with Inflammatory Bowel Disease: A German Claims Data Analysis. bio-experienced, bio-naive, IBD
37  2019 Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort. CD, p-VDZ, UC
38  2019 Real-world biologic treatment and associated cost in patients with inflammatory bowel disease. anti-TNFalpha, CD, IBD, UC
39  2019 The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis? GMA, UC
40  2019 Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. CD, CRP, IBD, MH, UC
41  2019 Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers. CD, HBI, IBD, MH, UC
42  2019 Vedolizumab-mediated integrin alpha4beta7 blockade does not control HIV-1SF162 rebound after combination antiretroviral therapy interruption in humanized mice. cART, MAdCAM-1, SIV
43  2018 A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. CD, HBI, IBD, pMS, UC, VTL
44  2018 Combining Anti-TNF-alpha and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. anti-TNFalpha
45  2018 Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center. CI, IBD, IFX, pw, TNF, UC
46  2018 Effect of vedolizumab (anti-alpha4beta7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. ---
47  2018 Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. anti-TNF, CD, CSFR, IQR, RWE, UC
48  2018 Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases. CD, UC
49  2018 Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease. CD, UC
50  2018 Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. anti-TNF, CD, CI, EIMs, IBD, IRR, PSC, UC
51  2018 Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease. AUROC, CD
52  2018 Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. CI, HR, IBD, LOR, TNF
53  2018 Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease. IBD, SSIs, TNFi
54  2018 Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study. IBD, PPV, RA, sMAdCAM-1, VTLs
55  2018 Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease. anti-TNF, CI, IBD, OR, UC
56  2018 Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease. CD, TDM, UC, UST
57  2018 Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. CD, IBD, UC
58  2018 Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. NRI
59  2018 Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. CD, CI, RWE, UC
60  2018 Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents. CD, UC
61  2017 Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time. AVA
62  2017 Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis. ETA, SpA
63  2017 Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience. AEs, CD, UC
64  2017 Fatal ulcerative enteritis of the small intestine in a patient with ulcerative colitis treated with vedolizumab. SIRS, UC
65  2017 Predictors of Clinical Response and Remission at 1Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. CD, HBI, IBD, UC
66  2016 The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. CD, CI, HR, PYF, TNF
67  2016 Vedolizumab for the treatment of ulcerative colitis. UC
68  2016 Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study. CD, CRM, CRS, UC
69  2015 Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. CD, UC
70  2015 Introducing vedolizumab to clinical practice: who, when, and how? anti-TNF, CD, IBD, UC
71  2014 Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies. ---
72  2013 In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. MAdCAM-1